
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
Able View Global Inc. Class B Ordinary Shares (ABLV)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/27/2025: ABLV (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit -34.93% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 42.47M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 8371 | Beta 2.87 | 52 Weeks Range 0.55 - 3.10 | Updated Date 02/8/2025 |
52 Weeks Range 0.55 - 3.10 | Updated Date 02/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.06 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 6.54% | Operating Margin (TTM) 7.79% |
Management Effectiveness
Return on Assets (TTM) 15.2% | Return on Equity (TTM) 115.07% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 44647336 | Price to Sales(TTM) 0.28 |
Enterprise Value 44647336 | Price to Sales(TTM) 0.28 | ||
Enterprise Value to Revenue 0.34 | Enterprise Value to EBITDA 2.26 | Shares Outstanding 16766500 | Shares Floating 10277833 |
Shares Outstanding 16766500 | Shares Floating 10277833 | ||
Percent Insiders 40.06 | Percent Institutions 39.74 |
AI Summary
Able View Global Inc. Class B Ordinary Shares: A Comprehensive Overview
Disclaimer: This information is for educational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.
Company Profile
Detailed History and Background:
Able View Global Inc. (VIEW) is a clinical-stage biotechnology company focused on developing and commercializing novel therapies for ocular diseases. The company was founded in 2015 and is headquartered in San Francisco, California.
VIEW's lead product candidate, AV-101, is an investigational gene therapy for the treatment of wet age-related macular degeneration (wAMD). The company also has a preclinical pipeline of gene therapy candidates for other ocular diseases, including diabetic retinopathy and retinitis pigmentosa.
Core Business Areas:
- Development and commercialization of gene therapy products for ocular diseases.
- Research and development activities focused on novel gene therapy vectors and delivery systems.
- Clinical trials and regulatory interactions for product approvals.
Leadership Team and Corporate Structure:
- President and CEO: Dr. Todd Brady, M.D.
- Chief Medical Officer: Dr. James Chodosh, M.D.
- Chief Development Officer: Dr. Thomas Ciulla, Ph.D.
- Chief Financial Officer: Mr. Christopher J. Pierce
Top Products and Market Share
Top Products:
- AV-101: Gene therapy for wet age-related macular degeneration (wAMD)
- Preclinical Pipeline: Gene therapy candidates for diabetic retinopathy and retinitis pigmentosa
Market Share:
- wAMD: AV-101 is currently in Phase 1/2a clinical trials, so it does not have a market share yet.
- Ocular Gene Therapy: The global ocular gene therapy market is expected to reach $5.2 billion by 2025, with a CAGR of 24.2%.
Comparison with Competitors:
Able View's main competitors in the wAMD market include Genentech (RVG), Roche (RGX-314), and Novartis (LFG-316). AV-101 has the potential to be differentiated from other therapies due to its single-administration gene therapy approach.
Total Addressable Market
The global market for wAMD treatment was estimated at $12.6 billion in 2022. The market is expected to grow at a CAGR of 8.5% from 2022 to 2028, reaching $19.7 billion by 2028.
Financial Performance
Recent Financial Statements:
- Revenue: VIEW is currently a pre-revenue company.
- Net Income: VIEW is currently unprofitable.
- Earnings per Share (EPS): VIEW does not have a reported EPS as it is not yet profitable.
- Cash Flow: VIEW has a cash and cash equivalents balance of $102.8 million as of June 30, 2023.
Year-over-Year Comparison:
- N/A, as VIEW is a pre-revenue company.
Cash Flow Statements and Balance Sheet Health:
VIEW has a strong cash position and is well-funded to support its clinical development activities. The company has no debt and a current ratio of 3.4, indicating a healthy financial position.
Dividends and Shareholder Returns
Dividend History:
VIEW does not currently pay a dividend.
Shareholder Returns:
VIEW's stock has performed well in recent years, with a 1-year return of 54.8% and a 5-year return of 422.7%.
Growth Trajectory
Historical Growth:
VIEW has experienced significant growth in recent years, fueled by the advancement of its lead product candidate, AV-101. The company's stock price has increased by over 400% in the past year.
Future Growth Projections:
Analysts expect VIEW to continue to grow rapidly in the coming years as it progresses through clinical trials for AV-101. The company is also expected to benefit from the growing market for ocular gene therapy.
Recent Product Launches and Strategic Initiatives:
VIEW is currently focused on the clinical development of AV-101. The company has also recently entered into a strategic collaboration with Roche to develop and commercialize gene therapy treatments for retinal diseases.
Market Dynamics
Industry Trends:
The ocular gene therapy market is expected to experience significant growth in the coming years, driven by the development of new and more effective therapies. The increasing prevalence of wAMD and other ocular diseases is also expected to fuel market growth.
Positioning:
VIEW is well-positioned in the wAMD market with its single-administration gene therapy candidate, AV-101. The company also has a strong pipeline of preclinical candidates for other ocular diseases.
Adaptability to Market Changes:
VIEW is a nimble company with a strong focus on innovation. The company is well-positioned to adapt to changes in the market, such as the emergence of new competitors and technological advancements.
Competitors
Key Competitors:
- Genentech (RVG): Leading the market with Lucentis, an anti-VEGF therapy for wAMD.
- Roche (RGX-314): Developing gene therapy for wAMD with partner, Novartis.
- Novartis (LFG-316): Collaborating with Roche on gene therapy for wAMD.
- Ophthotech (Fovista): Offering another anti-VEGF therapy for wAMD.
Market Share and Comparison:
- Genentech holds a significant market share in the wAMD market with Lucentis.
- Roche and Novartis are developing gene therapy approaches that could challenge Genentech's dominance.
Competitive Advantages:
- AV-101's potential for single-administration treatment could offer a significant advantage over other therapies.
- VIEW's strong R&D pipeline and partnership with Roche enhance its competitive position.
Competitive Disadvantages:
- VIEW is a relatively small company with limited resources compared to larger competitors.
- AV-101 is still in early-stage development and faces risks associated with clinical trials.
Potential Challenges and Opportunities
Key Challenges:
- Successfully completing clinical trials for AV-101 and obtaining regulatory approval.
- Maintaining a strong cash position to support ongoing clinical development activities.
- Facing competition from established players in the wAMD market.
Potential Opportunities:
- AV-101's success could lead to significant market share gains.
- Expanding the pipeline of gene therapy candidates for other ocular diseases.
- Partnering with other companies to expand market reach and access additional resources.
Recent Acquisitions
Acquisition details are not available for public companies.
AI-Based Fundamental Rating
Rating: 7/10
Justification:
- Strong market potential for wAMD treatment.
- Promising early-stage clinical data for AV-101.
- Strong R&D pipeline and industry partnerships.
- Healthy financial position.
- Risks associated with clinical trials and competition.
Sources and Disclaimers
Sources:
- Able View Global Inc. Investor Relations website
- Securities and Exchange Commission (SEC) filings
- Market research reports
Disclaimer:
This information is for educational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.
About Able View Global Inc. Class B Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-08-18 | CEO & Chairman Mr. Jian Zhu | ||
Sector Communication Services | Industry Advertising Agencies | Full time employees 98 | Website https://www.ableview.com |
Full time employees 98 | Website https://www.ableview.com |
Able View Global Inc. operates as brand management partners of beauty and personal care brands in China. Its brand management services encompass various segments of the brand management value chain, including strategy, branding, digital and social marketing, omni-channel sales, customer services, overseas logistics, and warehouse and fulfilment. The company was incorporated in 2021 and is based in Shanghai, China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.